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Objective: Cell-based technologies are considered to be a new approach for the treatment of
cerebral palsy (CP). Given the potent anti-inflammatory activity and high regenerative potential
of M2 macrophages, these cells may be a promising source for cell transplantation. To evaluate
the safety and efficacy of autologous M2 macrophages, we performed an open-label, Phase I/
II, non-controlled clinical trial in children with severe CP.
Patients and methods: Fifty-seven children with severe CP, including 33 boys and 24 girls,
with a median age of 4 years were enrolled in the study. The patients were treated with intrathecal
administration of autologous M2 macrophages. The primary outcome measure was safety, and
the secondary outcome measure was functional improvement in neurologic scales, including
the 66-item Gross Motor Function Measure test, Peabody Developmental Motor Scale-Fine
Motor test, Ashworth scale, Medical Resarch Council scale, and an easy-to-understand unified
questionnaire for evaluation of cognitive functions in our modification.
Results: Intrathecal introduction of M2 cells in a median dose of 11.2×106 did not induce any
serious adverse events either related with cell injection or during 5 years of follow-up. After 3
months, the Gross Motor Function Measure score increased from 19±4.5 to 77±7.8, the Peabody
Developmental Motor Scale-Fine Motor test score improved from 0.9±0.23 to 4.4±0.51, and the
Ashworth score decreased from 3.5±0.11 to 2.5±0.16. The assessment of cognitive functions
revealed an increase from 1.22±0.24 to 3.98±0.95, and a reduction of seizure syndrome was
registered. In addition, M2 injection was accompanied by an increased production of brainderived neurotrophic factor (pU=0.015).
Conclusion: The data obtained suggest that cell therapy based on M2 macrophages is safe,
does not induce any severe cell-related reactions or long-term side effects and comorbidities,
and is accompanied by significant neurologic improvements in severe CP patients.
Keywords: cerebral palsy, clinical study, cell-based therapy, M2 macrophages, neurologic
improvement
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Cerebral palsy (CP) is a non-progressive brain disorder, which is defined as a chronic
motor disability with various etiologies.1 It is closely associated with development
abnormalities or damage resulting from brain injury in utero or early infancy and is
accompanied by disturbances of sensation, perception, cognition, communication,
behavior, epilepsy, and secondary musculoskeletal problems.2–4 The pathophysiology
of CP is still largely unclear due to its heterogeneity and lack of relevant animal models. The most often prevalent pathological lesion in CP connected with the damage
of the corticospinal tracts is periventricular white matter injury and intraventricular
41
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hemorrhage. In both cases, inflammation is considered the
leading pathogenic factor that induces neural cell damage.5–7
Convincing evidence has been obtained pointing to the
association between inflammation and neonatal encephalopathy.8–10 Moreover, striking improvement in motor function following reduction of neuroinflammation in a rabbit
model of CP demonstrates the key role of inflammation in
the pathophysiology of CP.11
Currently, there are no effective treatments for CP which
can substantially improve motor and cognitive functions,
particularly in patients with moderate-to-severe disease, and
the best available therapies aim at functional, social, and
nutritional support.9,12
Given various disturbances in the brain tissue that involve
several cell types and multiple mechanisms, CP seems to be
an optimal target for cell therapy to repair the neurologic
functions.1,13,14 Actually, motor improvements following stem
cell administration were shown in animal models15,16 and
several clinical trials,17–19 which demonstrated the safety and
clinical improvement with mesenchymal stem cells, olfactory
ensheathing cells, neural progenitor cells, umbilical cord
blood stem cells, and neural stem cell-like cells.18–21
It has become obvious that along with the stem cells, the
monocytes/macrophages may be implicated in the repair of
the brain tissue and cerebral vasculature.22–24 Macrophages
have been classified as either M1 or M2 polarized populations. Whereas M1 macrophages are powerful inflammatory
cells that produce proinflammatory cytokines and phagocytize pathogens, M2 polarized macrophages modulate the
inflammatory responses and stimulate angiogenesis and
tissue repair.25,26 In the central nervous system (CNS), local
microglia and newly recruited circulating blood monocytes
can polarize toward the M2 cells and ameliorate CNS damage. The capacity of macrophages to stimulate neural repair
was firstly demonstrated in spinal cord injury models.27–29
Later, experimental studies in stroke model also demonstrated that M1 polarized macrophages are neurotoxic,
whereas M2 cells protect the neurons from apoptosis, 30
and that administration of monocytes as a part of human
umbilical cord blood monocytes reduces the infarct size
and restores motor function.24 Similarly, the recovery of
astrocytes, oligodendrocytes, endothelial cells, and myelin
in the lipopolysaccharide-injured brain was shown to occur
after infiltration of monocytes.31
The clinical data available to date have demonstrated a
therapeutic potential of stem cells,32 but there are no clinical
reports on macrophages in the treatment of CP. Nevertheless,
several groups have proposed that cell products composed
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of human monocytes could be considered as candidates for
the treatment of injury-induced CNS demyelination.23,33,34
Recently, we designed a new protocol for the generation of
M2-like macrophages using low growth factor c onditions.35
These cells differ from M1 cells by higher expression of
M2-accosiated (CD206) and proapoptogenic (B7-H1,
TRAIL, FasL) molecules and lower production of many proinflammatory cytokines and chemokines. In addition, these
macrophages are unable to stimulate effective T-cell proliferation in mixed lymphocyte reaction as well as to induce
Th1/Th17 response, and possess considerable regenerative
potential (in particular, produce high amounts of insulin-like
growth factor 1 and vascular endothelial growth factor). This
study aimed to assess the safety of M2 cell transplantation in
severe CP patients and the efficacy of transplanted M2 cells
in neurologic improvement.

Patients and methods
Study design and patient enrollment
An open-label, Phase I/II, non-controlled clinical study of
chronic children who had severe CP was conducted. The
purpose of this study was to assess the safety and therapeutic
efficacy of M2-like macrophages for treatment of CP patients.
A written informed consent was obtained from the patients’
parents before the therapy. Permission for this study was
obtained from the Academic Board and Review Board (Local
Ethics Committee) of the Research Institute of Fundamental
and Clinical Immunology (Novosibirsk, Russia).
Patients with CP were considered eligible if they fulfilled
the following inclusion criteria: 1) age ≥12 months and ≤10
years; 2) performance status: Gross Motor Function Classification System – level IV–V; 3) parental consent. The exclusion criteria were: 1) autism and autistic spectrum disorders
without motor disability; 2) progressive neurologic disease;
3) human immunodeficiency virus or uncontrolled bacterial,
fungal, or viral infections; 4) impaired renal or liver function;
5) genetic disease or phenotypic evidence of a genetic disease
on physical examination; 6) requires ventilatory support; and
7) unable to obtain parental consent.

Macrophage generation and introduction
The generation of macrophages from peripheral blood plasticadherent cells was performed according to the previously
developed protocol.35 In brief, adherent cells were cultured
in RPMI-1640 (BioloT, St. Petersburg, Russia) with supplements at 37°C with 5% CO2. To obtain M2-like macrophages,
we used recombinant human granulocyte-macrophage
colony-stimulating factor (50 ng/mL; R&D Systems, Inc.,
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Minneapolis, MN, USA) and serum deprivation conditions (low percentage of autologous plasma). In 7 days, the
macrophages were harvested by using EDTA in Hanks’ balanced salt solution (all reagents from Sigma-Aldrich Co., St
Louis, MO, USA), washed, and counted. Then, the generated
M2-like macrophages were resuspended in 2 mL sodium
chloride 0.9% and infused into spinal cord fluid of the patient.

Measurement of safety and efficacy
All patients were estimated before cell therapy, 3 months after
cell therapy, and followed up for the following 5-year period.
The primary outcome measure was safety, which included
assessment of mortality of any cause and immediate adverse
reactions as well as long-term side effects and comorbidities.
The secondary outcome measure was functional improvement in neurologic scales, including Gross Motor Function
Measure (66-item GMFM) test, Peabody Developmental
Motor Scale-Fine Motor test, Ashworth scale, Medical
Research Council (MRC) scale, and easy-to-understand
unified questionnaire for evaluation of cognitive functions in
our modification. Gross motor abilities were characterized
by six functions (head controlling, rolling, crawling, sitting,
standing, and walking). Fine motor development was evaluated on five functions (hand movement in the midline, active
grasping of objects, shifting the objects from one hand to the
other, pinching of tiny objects, and “eye–hand” coordination).
Five-point Ashworth scale was used for evaluating the degree
of spasticity, and six-point MRC weakness scale served
for muscle strength estimation. Cognitive functions were
estimated based on six functions (understanding addressed
speech, speaking of single words, aggression, contact with
outsiders, recognizing relatives, and meaningful glance).
To evaluate the influence of M2 therapy on endogenous
production of brain-derived neurotrophic factor (BDNF), the
samples of patient serum were collected before and a month
after macrophage introduction and frozen at −80°C until the
measurement. The concentration of BDNF was determined
using enzyme-linked immunosorbent assay following the
instructions of manufacturers (R&D Systems, Inc.).

Statistical analysis

Data were expressed as means ± standard error and median
(Me) with interquartile range (lower quartile–upper quartile).
Statistica 6.0 software for Windows (StatSoft Inc., Tulsa,
OK, USA) was used for analysis of data. Fisher’s exact test
was used to determine the relationships between categorical
variables. Wilcoxon matched pairs test and Mann–Whitney
U test were used to compare nonparametric values.
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Results
Fifty-seven patients (33 boys and 24 girls) with severe CP
were enrolled in the current study (Table 1). The Me age was 4
years (range 1–10 years). The vast majority of children (84%)
had the fifth level of movement abnormalities estimated by
Gross Motor Function Classification System. The types
of CP were as follows: 25 spastic quadriplegia, 26 double
hemiplegia, 6 others (ataxic, athetoid, triplegia). According
to the computed tomography findings, the leading cause of
CP was brain atrophy (65%), indicative of hypoxic–ischemic
brain damage, along with intracranial hemorrhage (9%) and
unknown causes (26%).
The GMFM-66 score at entry was 19.4±4.47. Evaluating
the degree of spasticity based on Ashworth scale evidenced
a considerable (4–5 point) increase in muscle tone in 39/57
(68%) CP children with an average Ashworth score of
3.5±0.11. The MRC weakness score reflecting muscle
strength in forearms was 1.28±0.14, which indicated a
marked reduction in muscle strength in all children at baseline. Twenty-nine children had epileptic seizures requiring
anticonvulsant therapy. Mental faculties were impaired in
practically all patients. Actually, 48 patients (84%) were
unable to speak and 42 children (73%) could not understand
the addressed speech.
All patients received one grafting of autologous
M2-like macrophages. On average, 11.6±0.86×106 M2-like
Table 1 Baseline characteristics of 57 patients
Parameters

Mean ± SEM (Me; LQ–UQ)

Age, years
Boys/girls
Body weight, kg
CP type
Spastic quadriplegia
Double hemiplegia
Athetoid quadriplegia
Mixed quadriplegia
GMFCS
Level III
Level IV
Level V
Seizures
GMFM
Ashworth scale
MRC scale
Fine motor, PDMS-FM
Cognition
Cell number, 106

4.8±0.33 (4; 3–7)
33/24
15.6±1.05 (13; 12–17)
24 (42.1%)
26 (45.6%)
2 (3.5%)
5 (8.8%)
3 (5.3%)
6 (10.5%)
48 (84.2%)
29/57 (50.8%)
19.4±4.47 (0; 0–28)
3.5±0.11 (4; 3–4)
1.28±0.14 (1; 0–2)
0.9±0.23 (0; 0–0)
1.22±0.24 (0; 0–2)
11.6±0.86 (11.2; 5.2–16.2)

Abbreviations: CP, cerebral palsy; GMFCS, Gross Motor Function Classification
System; LQ–UQ, lower quartile–upper quartile; Me, median; MRC, Medical
Research Council; PDMS-FM, Peabody Developmental Motor Scale-Fine Motor;
SEM, standard error of the mean.
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 acrophages (Me 11.2×106, range 5.2–16.2) were used for
m
intrathecal introduction. The viability of obtained cells in all
cases exceeded 93%. Patients were evaluated for neurologic
changes 3 months after therapy and further monitored up
to 5 years. An overall improvement was defined as a score
change in GMFM >4 points.
Endolumbar administration of M2-like cells was generally well tolerated. After transplantation, mild fever was
observed in 31 patients (54%) and 13 patients (22.8%) had
intermittent vomiting. These cell therapy-related reactions
were only observed during the first 2 days and were well managed with medications Dexasone (KRKA Pharma, Moscow,
Russia), Metoclopramide (AWD Pharma GmbH & Co. KG,
Dresden, Germany). No cases of immediate severe adverse
events such as allergic reactions, local hematoma or infections at the site of lumbar puncture, meningeal reactions, and
systemic inflammatory or toxic complications were noted
after cell introduction. At the 3-month follow-up, no signs of
neurologic worsening, appearance of new seizure episodes, or
increase in the frequency of existing episodes, as well as other
serious comorbidities (dyspepsia, infections, and so on) were
observed. However, one child demonstrated exacerbation of
atopic dermatitis. Till the end of follow-up period, all patients
were alive and had no long-term comorbidities and tumors.
After 3 months, all scales showed remarkable improvement from the baseline score. Overall therapeutic responses
are shown in Table 2 and Figure 1. It is evident from Table 2
that gross and fine motor activities as well as the muscle
strength were enhanced significantly (p<0.01). In addition, a
significant decrease in spasticity was also observed at 3 months
after transplantation (p<0.01). Finally, cell therapy resulted in
obvious improvement of cognitive functions (p<0.01).
Favorable clinical outcome was noted in 42/57 cellgrafted CP children (73%; responding group). The majority
of children enrolled in our investigation could not independently keep their head in a vertical position (41/57; 72%)

Table 2 Neurologic examination of CP children (N=57) over a
3-month observation period after M2 macrophage introduction
Scales

Before M2
introduction

After M2
introduction

GMFM-66
Ashworth
MRC
Fine motor activity
Cognition

19.4±4.47 (0; 0–28)
3.5±0.11 (4; 3–4)
1.28±0.14 (1; 0–2)
0.9±0.23 (0; 0–0)
1.22±0.24 (0; 0–2)

73±7.8 (64; 8–124)**
2.5±0.16 (2; 1–4)**
2.5±0.15 (3; 2–3)*
4.4±0.51 (3; 0–8)**
3.98±0.95 (4; 2.5–5.5)**

Notes: *p<0.05, **p<0.01 (Wilcoxon matched pairs test).
Abbreviations: CP, cerebral palsy; GMFM, Gross Motor Function Measure; MRC,
Medical Research Council.
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and had no capacity to crawl and roll over (48/57; 84%).
With M2 therapy, 34 children out of 41 (82%) were able
to keep the head and 31 children (64%) were able to crawl.
Moreover, CP children treated with M2 cells displayed an
obvious improvement in toy manipulations, grasping, and
visual–motor integration (Figure 1). The beneficial effects
of cell therapy appeared not only in motor activities, but
also in cognitive/mental functions. In fact, we observed a
decrease in aggression (38/42) and improvement of contact
with outsiders (34/52). Sixteen of 42 children understood or
improved their understanding of the addressed speech, and 12
of 51 children showed the appearance of a meaning-bearing
speech. Of importance, 10/29 children (34%) with seizure
syndrome (up to 10 episodes per month) experienced seizure
arrest, and another 14 children exhibited significantly reduced
seizure frequency (from 7–10 to 1–2 episodes per month).
The improvement of motor functions and mental abilities
appeared quite early, from several days to 1 month, was
clearly manifested at 3 months, and did not reduce over time.
By comparing the children responding and not responding to cell therapy, we found that the better outcomes did not
depend on some demographic parameters (age or sex) and
severity of neurologic deficit as well as the number of input
cells. However, the children who responded to cell therapy
showed a trend to have higher GMFM scores than the nonresponders (23.2±5.5 vs 6.8±6.8, p=0.066).
Finally, to evaluate the influence of M2 therapy on endogenous neurotrophic factor production, we examined the concentration of BDNF in the serum of CP children 1 month after
M2 administration. The data showed that the macrophage
injection was accompanied by an increased production of
BDNF (from 695±60 to 1183±153 pg/mL; pU=0.015), which
was more pronounced in the responding group.

Discussion
Recent studies have demonstrated that cell-based therapy can
improve neurologic functions in various neuropathologies
including CP.14,36,37 Along with stem cells and their derivatives, a major role of M2 anti-inflammatory macrophages
in promoting neural repair was documented.27,29 The idea
on the beneficial role of macrophages in CNS repair was
firstly proposed by the group of Michal Schwartz which
demonstrated that implantation of the macrophages into
transected rat spinal cord stimulated tissue repair and partial recovery of motor function.38 Later, this group initiated
a pilot Phase I study of M2-like macrophage implantation
in patients with acute complete spinal cord injury38 and a
Phase II randomized controlled multicenter trial.40 Despite
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Figure 1 The improvement in motor and mental activities in CP patients at 3 months after M2 macrophage treatment.
Note: Data are presented as the percentage of positive cases in patients who initially were unable to perform the function.
Abbreviation: CP, cerebral palsy.

the lack of an obvious clinical improvement due largely to the
invasiveness of implanting procedure, the clinical trial was
a major achievement to transfer macrophage-based therapy
into clinic. Immunomodulation by M2 macrophages may
partially underlie the effect of stem cell-based therapy, since
many transplanted cells die from apoptosis and engulfment
of apoptotic cells by macrophages induces M2 polarization.41
Another possibility is that transplanted mesenchymal stem
cells can “educate” macrophages toward an immunoregulatory phenotype.42
This study provides the first evidence of the possible
application of M2 macrophages for the treatment of CP. We
utilized our original approach to obtained M2 cells using
low growth factor conditions35 and have shown that M2
macrophages may be successfully generated in children with
severe CP. Intrathecal introduction of these M2 macrophages
was shown to be safe, well tolerated, and did not result in
immediate adverse reactions and long-term side effects and
comorbidities. In one patient, an aggravation of atopic dermatitis was registered, and we attribute this to the possible
Th2-stimulating capacity of M2.43 Certainly, this fact requires
a careful examination of patients for allergic diseases and may
be the exclusion criterion for M2 macrophage application in
children with severe and diffuse forms of atopic pathology.
On the other hand, exacerbation of atopic dermatitis in only
Journal of Neurorestoratology 2018:6

1/57 patients evidenced that endolumbar application of macrophages did not induce systemic activation of Th2 response.
The important result of this study is the analysis of long-term
adverse effects after 5-year follow-up demonstrating that
there was no case of neurologic worsening, appearance of
new episodes or enhancement of seizures, or development
of tumor during this period.
In our study, there was no control group and the only
possibility to evaluate the effect of transplanted cells was the
comparison of motor function and cognitive abilities before
and after therapy. M2 macrophage implantation was accompanied by significant decrease in spasticity and enhancement
of muscle strength and GMFM scores along with a marked
improvement in cognitive functions. Importantly, functional
improvement appeared quite early (from some days to 1
month), which was consistent with the observations of other
researchers.18–20 Once the improvements appeared, they did
not decrease with time. Given that the majority of patients
recruited to our clinical trial had the fifth level of disability,
did not display any improvement after 3–6 months of standard
rehabilitation training before cell therapy, were older than 3
years (64% of patients), and displayed early manifestation
of the improvement, we suggest that the positive effects
were not the result of rehabilitation therapy or age-related
development, but were primarily mediated by transplanted
submit your manuscript | www.dovepress.com
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cells. Of importance is the fact that M2 therapy ameliorates
seizure syndrome. This is confirmed by full arrest of seizures
in 10 persons and pronounced decrease in the rate of seizure
episodes in another 14 children out of 29 patients having
seizure syndrome.
Our results concerning the possibility of cell therapy to
improve psychomotor functions in CP are consistent with
others. Chen et al showed that fetal olfactory ensheathing
cells (OECs) injected into the bilateral corona radiata in the
frontal lobes resulted in a significant increase in GMFM score
and improvement of mental functions in CP.18 Luan et al demonstrated similar results utilizing intracerebral implantation
of allogeneic neural progenitor cells.19 The efficacy of cord
blood stem cells was demonstrated by Min et al, who showed
amelioration of motor and cognitive impairments following
infusion of allogeneic umbilical cord blood potentiated with
recombinant human erythropoietin.21
The mechanisms by which M2 macrophages promote
neurologic improvement in CP patients are not quite clear.
According to our previous data, M2 cells are capable of spontaneous production of BDNF, insulin-like growth factor 1,
epidermal growth factor (EGF), basic fibroblast growth factor (FGFb), granulocyte-colony stimulating factor (G-CSF),
erythropoietin, and vascular endothelial growth factor35 that
possess neuroprotective activity and stimulate CNS regeneration.44–47 Therefore, our findings concerning increase in
serum BDNF after cell therapy can argue this hypothesis.
Recent findings also showed the capacity of monocytes/
macrophages to differentiate into endothelium-like cells and
function as precursors of endothelial cells48 participating in
vascular repair.49 A rapid functional improvement is probably
related to the activation of “silent” synapses. Finally, given
the major role of inflammatory mediators in the pathogenesis of CP,10 a functional improvement may be mediated by
the immunomodulatory activity of M2 cells. Reduction of
neuroinflammation in the models of CP leads to an improvement in motor function. In this regard, it should be noted that
the M2 cells generated in our protocol differ from M1 cells
by higher expression of several proapoptogenic molecules
(B7-H1, TRAIL, and FasL), which can induce apoptosis of
activated immune cells and downregulate the inflammatory
response. In any case, further investigations are required to
better understand the precise mechanisms underlying the
therapeutic effects of M2 cells.
The advantages of M2 macrophages are the safety and
feasibility of the procedure, since it involves utilization
of autologous cells generated from peripheral blood, and
intrathecal delivery that is less invasive as compared to intra-

46

submit your manuscript | www.dovepress.com

Dovepress

cerebral implantation of candidate cells. Another p rivilege
is that M2 transplantation has a stable effect and may be
carried out in children with seizure syndrome. However, to
better define the therapeutic effects of M2 macrophages and
to elucidate the mechanism of M2 cells in CP, further studies
should be performed.

Conclusion
The data obtained suggest that cell therapy based on M2
macrophage administration is safe, does not induce any
severe cell-related reactions or long-term side effects and
comorbidities, and is accompanied by significant neurologic
improvements in severe CP patients.
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